Clinical Trial Update: Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate the efficacy and safety of CMG190303 in patients with Type 2 diabetes mellitus and dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• CMG190303

Snippet

Sponsor: CMG Pharmaceutical Co. Ltd | Conditions: Dyslipidemia, Type 2 Diabetes | Phase 3 | Status: RECRUITING